Short Term Pre-Operative Endocrine Therapy Helps Clarify Patient Tolerance to Guide Post-Operative Treatment Decisions

Informs Radiation Decision-Making for Older Women with Early-Stage Breast Cancer

A 90-day course of pre-operative endocrine therapy (ET) provides insight into a patient’s tolerance for these drugs and helps inform a decision between post-surgical radiation therapy (RT) and ET for women age 65 and older with hormone receptor-positive invasive breast cancer. These were the results of a new study recently presented at the American Society of Breast Surgeons Annual Meeting.

“For older women with this cancer profile, long-term data from large clinical trials support omission of RT after lumpectomy when patients take a five to 10-year course of post-operative ET,” notes Shayna Showalter, MD, study lead investigator and Professor of Surgery at the University of Virginia. “However, because ET side effects cause some women to discontinue the drugs without completing the full course, today most women are also treated with RT.”

Now, the phase II, multi-center POWER Trial finds that a short course of pre-operative ET allows women to assess their tolerance for the therapy and significantly alters patient preference and physician recommendations for post-operative treatment. “Those who tolerate ET well during the pre-operative period can forgo RT and choose drug therapy with greater assurance in their ability to complete their post-operative ET regime,” says Dr. Showalter. Without RT, she points out, patients who do not take the full course of ET are undertreated for their disease.

“Conversely, women who experience significant negative reactions to pre-operative ET can choose RT with greater confidence that this is most appropriate for them,” she says. “They do not necessarily need both post-operative therapies, which would represent over-treatment.”

“The goal,” she says, “is to optimize treatment for individual patients.”

The final POWER Trial cohort involved 74 women age 65 and older with early-stage, hormone receptor-positive breast cancer who chose breast conserving surgery. For pre-operative ET, patients received either aromatase inhibitors (85.3%) or tamoxifen (14.6%). Prior to and following this initial treatment, patients and their doctors completed surveys regarding their preference for adjuvant RT. After the pre-operative ET period, 21 patients (28%) and 18 surgeons (24%) changed their preference for RT, which was statistically significant.

Despite this change, most patients expressed confidence in their adjuvant therapy choice in both pre- and post-therapy surveys, suggesting that the initial course of ET provided valuable information to improve decision-making.

Of the 45 patients (60%) who initially reported a significant resistance to RT, 11 later expressed a likelihood of pursuing it. “Presumably, these women experienced side effects during the pre-operative endocrine period that were sufficient enough to persuade them to consider RT,” Dr. Showalter comments.

Of the 30 women who initially expressed a preference for RT, 10 indicated in follow-up surveys that they were now unlikely to choose radiation. “Probably these women came to view ET more favorably because they did not experience the anticipated negative reactions,” she says.

Dr. Showalter notes that the study findings validate pre-surgical ET as an effective method to drive more informed patient and physician decision-making about adjuvant therapies. “The POWER II trial, now underway, explores whether the short course of pre-operative ET will lead to less over- and under-treatment in adjuvant treatment in this population,” she says.

“Today, as cancer care becomes more patient-focused and individualized, these studies are important,” Dr. Showalter notes. “They may bring about a paradigm shift in treatment of older women with early-stage breast cancer by supplying important information for enhanced therapy planning.”